Literature DB >> 23255296

Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.

Yiming Zhang1, Zhenghui Guo, Tao Du, Jieqing Chen, Wei Wang, Kewei Xu, Tianxin Lin, Hai Huang.   

Abstract

BACKGROUND: Regulated activation of p38 is crucial for cell proliferation, survival, and metabolism. Our previous studies had showed that prostate specific membrane antigen (PSMA) can facilitate the proliferation, migration, survival of the LNCaP prostate cancer cell line, but the mechanisms are poorly defined.
METHODS: Our LNCaP cells had been stably transfected with lentivirus-mediated shRNA for PSMA silencing in previous study. We first testify the efficacy of PSMA knockdown in our LNCaP cell line. Then using this PSMA (-) LNCaP cell line, we compared the expression of PSMA and P-p38 by Western blotting among groups. Furthermore, we also performed immunofluorescence to confirm the change of P-p38 in cells. Then, cell viability and migration were measured by cell counting kit-8 reagent and Transwell analysis respectively. Flow cytometry was employed to evaluate cell survival.
RESULTS: After silencing the expression of PSMA, the level of the phospho-p38 (P-p38) decreased approximate 40% compared with the blank and NC groups (P < 0.05). When the cells were incubated with SB203582 (p38 inhibitor), the P-p38 in three groups was at low level and no difference among groups (P > 0.05). Then the results of immunofluorescence further proved the relationship between PSMA and P-p38. Decrease of cell viability, migration, and survival was observed upon PSMA silencing. SB203580, a specific inhibitor of p38 MAPK pathway, also reduced proliferation, migration, and survival of LNCaP cells.
CONCLUSION: These data suggests PSMA may stimulate prostate cancer cells proliferation, migration and survival through p38 MAPK pathway, revealing a novel mechanism for PSMA playing positive role on LNCaP cells.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23255296     DOI: 10.1002/pros.22627

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  11 in total

Review 1.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

2.  Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.

Authors:  Daniele Baiz; Sazzad Hassan; Young A Choi; Anabel Flores; Yelena Karpova; Dana Yancey; Ashok Pullikuth; Guangchao Sui; Michel Sadelain; Waldemar Debinski; George Kulik
Journal:  Neoplasia       Date:  2013-10       Impact factor: 6.218

3.  A comparison of the biological features of prostate cancer with (PSA+, PSMA+) profile according to RKIP.

Authors:  Awatef Ben Jemaa; Yosra Bouraoui; Sataa Sallami; Yassine Nouira; Ridha Oueslati
Journal:  Biomed Res Int       Date:  2013-08-07       Impact factor: 3.411

4.  TES inhibits colorectal cancer progression through activation of p38.

Authors:  Huili Li; Kun Huang; Lu Gao; Lixia Wang; Yanfeng Niu; Hongli Liu; Zheng Wang; Lin Wang; Guobin Wang; Jiliang Wang
Journal:  Oncotarget       Date:  2016-07-19

5.  Intracellular signaling pathway in dendritic cells and antigen transport pathway in vivo mediated by an OVA@DDAB/PLGA nano-vaccine.

Authors:  Shulan Han; Wenyan Ma; Dawei Jiang; Logan Sutherlin; Jing Zhang; Yu Lu; Nan Huo; Zhao Chen; Jonathan W Engle; Yanping Wang; Xiaojie Xu; Lei Kang; Weibo Cai; Lianyan Wang
Journal:  J Nanobiotechnology       Date:  2021-11-27       Impact factor: 10.435

Review 6.  The present and future of prostate cancer urine biomarkers.

Authors:  Marina Rigau; Mireia Olivan; Marta Garcia; Tamara Sequeiros; Melania Montes; Eva Colás; Marta Llauradó; Jacques Planas; Inés de Torres; Juan Morote; Colin Cooper; Jaume Reventós; Jeremy Clark; Andreas Doll
Journal:  Int J Mol Sci       Date:  2013-06-17       Impact factor: 5.923

7.  Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells.

Authors:  Claire B Pollock; Sara McDonough; Victor S Wang; Hyojung Lee; Lymor Ringer; Xin Li; Cristina Prandi; Richard J Lee; Adam S Feldman; Hinanit Koltai; Yoram Kapulnik; Olga C Rodriguez; Richard Schlegel; Christopher Albanese; Ronit I Yarden
Journal:  Oncotarget       Date:  2014-03-30

Review 8.  Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients.

Authors:  Floor C J van de Watering; Mark Rijpkema; Lars Perk; Ulrich Brinkmann; Wim J G Oyen; Otto C Boerman
Journal:  Biomed Res Int       Date:  2014-05-28       Impact factor: 3.411

Review 9.  Targeting strategies of adenovirus‑mediated gene therapy and virotherapy for prostate cancer (Review).

Authors:  Zhonglin Cai; Haidi Lv; Wenjuan Cao; Chuan Zhou; Qiangzhao Liu; Hui Li; Fenghai Zhou
Journal:  Mol Med Rep       Date:  2017-09-13       Impact factor: 2.952

Review 10.  The Role of Testin in Human Cancers.

Authors:  Aneta Popiel; Christopher Kobierzycki; Piotr Dzięgiel
Journal:  Pathol Oncol Res       Date:  2018-10-25       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.